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The normal adult human mammary gland is a contin-
uous bilayered epithelial system. Bipotent and
myoepithelial progenitors are prominent and unique
components of the outer (basal) layer. The inner
(luminal) layer includes both luminal-restricted pro-
genitors and a phenotypically separable fraction
that lacks progenitor activity. We now report an epi-
genomic comparison of these three subsets with one
another, with their associated stromal cells, and with
three immortalized, non-tumorigenic human mam-
mary cell lines. Each genome-wide analysis contains
profiles for six histone marks, methylated DNA, and
RNA transcripts. Analysis of these datasets shows
that each cell type has unique features, primarily
within genomic regulatory regions, and that the cell
lines group together. Analyses of the promoter and
enhancer profiles place the luminal progenitors in
between the basal cells and the non-progenitor
luminal subset. Integrative analysis reveals networks
of subset-specific transcription factors.
INTRODUCTION
The normal adult human female mammary gland is a continuous
bilayered, branching epithelial structure containing three pheno-
typically distinct subsets of cells. These can now be isolated and
biologically distinguished (Fu et al., 2014). They are referred to as
basal cells (BCs), luminal progenitors (LPs), and luminal cells
(LCs) because their surface marker expression profiles identify
their location within the outer (basal) or inner (luminal) layer of
the gland. A prominent fourth cell population in the breast is
comprised of mesodermally derived stromal cells (SCs). Approx-
imately 20%–30% of human mammary BCs and LPs have
progenitor (clonogenic) activity demonstrable in both 2D and2060 Cell Reports 17, 2060–2074, November 15, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://3D cultures (Eirew et al., 2008; Kannan et al., 2013; Raouf
et al., 2008). Most colonies derived from the BCs contain a
mixture of cells with either basal or luminal features, although
sometimes only basal progeny are produced. Human LPs
contain all of the in vitro progenitor activity of the luminal
compartment and produce colonies of cells expressing luminal
features exclusively. Because LCs lack substantial proliferative
potential in vitro, they are assumed to represent a mature subset
of luminal cells (Fridriksdottir et al., 2015; Kannan et al., 2013).
When transplanted into immunodeficient mice, a small propor-
tion (<1%) of human BCs, but not LPs or LCs, can also individu-
ally regenerate normal-appearing bilayeredmammary structures
that contain the same spectrum of cell types and progenitors
found in the normal human gland. This property suggests the
cells of origin of these structures represent a human mammary
stem cell population (Eirew et al., 2008; Kuperwasser et al.,
2004; Lim et al., 2009; Nguyen et al., 2014).
Despite these advances, the molecular regulators that specify
the unique features of each of these normal human mammary
subsets have only recently become amenable to interrogation.
Transcriptome profiling (Choudhury et al., 2013; Gascard et al.,
2015; Huh et al., 2015; Kannan et al., 2013; Lim et al., 2009,
2010; Makarem et al., 2013; Maruyama et al., 2011; Raouf
et al., 2008; Dos Santos et al., 2015), together with functional
studies, has enabled several key transcription factors (TFs) to
be identified in the subpopulations of normal human as well as
analogous mouse mammary cell types (Fu et al., 2014; Visvader
and Stingl, 2014). Thus implicated in BCs are SLUG, TP63 and
TP53, SOX9, STAT3, MYC, and TAZ. In cells with luminal fea-
tures, CEBPB and NOTCH3 (Raouf et al., 2008), together with
GATA3, ELF5 (Chakrabarti et al., 2012), and FOXA1, which reg-
ulates estrogen receptor activity (Theodorou et al., 2013), have
been identified as important.
Previous human mammary epigenome profiles produced as
part of the Roadmap Epigenomics Consortium (Roadmap Epi-
genomics Consortium et al., 2015) have provided an initial global
annotation of active enhancer regions (Gascard et al., 2015). We
now report a more extensive set of reference epigenome profilesuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Isolation of Purified Cell Subsets and Epigenomic Profiling
(A) Experimental design.
(B) Unsupervised clustering of RNA-sequencing experiments comparing the samples analyzed in this study (CEMT) with other studies (Nguyen et al., 2015;
Roadmap Epigenomics Consortium et al., 2015; Gascard et al., 2015).
(legend continued on next page)
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that include a separate analysis of human LPs and LCs and pro-
files for SCs isolated from the same normal breast tissue, as well
as profiles generated from three widely used immortalized, but
non-tumorigenic, human mammary epithelial cell lines: i.e.,
MCF-10A cells (Debnath et al., 2003) and 184-hTERT-L2 (184-
L2) and 184-hTERT-L9 (184-L9) cells (Burleigh et al., 2015).
The results demonstrate that the cell lines are not representative
of any freshly isolated normal human mammary subset. They
have also allowed a hierarchy of enhancer states in normal
human mammary tissue and their corresponding cell-specific
TF networks to be identified.
RESULTS AND DISCUSSION
Generation and Validation of Comprehensive Reference
Epigenomes
Reference epigenomic profileswere generated following the rec-
ommendations of the International Human Epigenome Con-
sortium (IHEC; http://ihec-epigenomes.org). The subsets of
normal human breast cells isolated were >95% pure CD49f+
EPCAMlow/ cells (BCs), CD49f+EPCAMhigh cells (LPs), CD49f
EPCAMhigh cells (LCs), and CD49fEPCAM cells (SCs). These
subsets were initially isolated separately from each of six donor
samples (aged 17-49 years) using gates that excluded CD45+
hematopoietic cells, CD31+ endothelial cells, and dead (DAPI+)
cells (Figures 1A and S1). Like fractions of cells from each
sample were then pooled for epigenomic profiling. In vitro 2D
colony-forming cell (CFC) assays confirmed the expected
content of mammary progenitors in each subset (24% of
BCs, 18% of LPs, and <0.3% of LCs). Chromatin immunopre-
cipitation sequencing (ChIP-seq) data for six histone marks
(H3K4me3, H3K4me1, H3K27ac, H3K27me3, H3K9me3, and
H3K36me3), whole-genome bisulfite sequencing (WGBS), and
RNA sequencing (RNA-seq) datasets (both mRNA and miRNA)
were obtained for all four subsets. Parallel data were obtained
on MCF-10A cells and 184-L2 and 184-L9 cells. Fully anno-
tated tracks can be viewed in current genome browsers
or downloaded directly for offline analysis at http://www.
epigenomes.ca. Quality measures and methods to access the
raw and processed data are provided in Experimental Proced-
ures and Table S1.
Unsupervised hierarchical clustering analysis of the transcrip-
tome data indicated all three mammary epithelial subsets are
more similar to each other than to the SCs but, nevertheless,
distinct, with the LPs clustering closer to LCs than BCs. (Fig-
ure 1B). Paired comparison of the gene expression profiles
confirmed a similarity of LP and LC transcriptomes (p < 0.001,
Mann-Whitney) across both protein coding (Figures 1C and
S2B; Table S2) and non-coding space (Figure S2C; Table S3).(C) Differential gene expression analysis for protein-coding genes. Each dot-pl
(green), and those with downregulated expression (red). Bottom right panel: boxp
made.
(D) Unsupervised clustering of miRNA sequencing data for the samples analyzed
(Gascard et al., 2015).
(E) Heatmap showing the expression (Z scores) of the 100 genes with the largest
gene differentially expressed between the primary epithelial subpopulations profi
See also Figures S1 and S2 and Tables S1, S2, and S3.
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ported findings obtained both by RNA-seq (Gascard et al.,
2015; Nguyen et al., 2015) and by 30 tag-based and microarray
analysis (Kannan et al., 2013; Lim et al., 2009; Raouf et al.,
2008), including an identification of many of the same genes as
‘‘BC specific’’ (e.g., TP63 (deltaN), ACTA2, MME, KRT14,
THY1, and KRT5) or ‘‘LP specific’’ (e.g., MUC1, PROM1, KIT,
KRT18, EPCAM, and KRT8) (Figure S2A). Similar clustering
and differences between the same four cell types were
observed when either microRNA (miRNA) or large intergenic
noncoding RNA (lincRNA) profiles were analyzed (Figures 1D,
S2D, and S2E).
Notably, the transcriptomes for all three immortalized human
mammary cell lines clustered independently from both the pri-
mary epithelial subsets and the SCs isolated directly from the
same freshly dissociated normal humanbreast tissue (Figure 1B).
Moreover, 66 of the 100 genes whose differential expression
contributed most to the separate clustering of the mammary
cell lines (highest rank differences) included genes of known
importance in the mammary gland (e.g., PROM1, KIT, CXCR4,
SOX10, ELF3, RARRES1, MMP7, TGFBI, and NT5E) and were
found to be differentially expressed in the different subsets of pri-
mary epithelial cells (Figure 1E). These results show that these
culture-adapted immortalized cell lines, commonly used as
models of ‘‘normal’’ human mammary cells, exhibit significant
and consistent differences in their transcriptional profiles from
all subsets of epithelial mammary cells isolated directly from
normal human breast tissue.
Variations in the Chromatin States of Different Normal
Human Breast Cell Phenotypes
To examine and compare the chromatin states of the same pri-
mary breast cell types as well as the three cell lines, we used
ChromHMM (Ernst and Kellis, 2012) to generate an 18-state
model from the ChIP-seq profiles (Figures 2A and 2B). The re-
sults recapitulate many features of the 18-state model recently
published for 111 primary human tissues and cell types (Road-
map Epigenomics Consortium et al., 2015), including the
reported relationship between chromatin states and DNA
methylation (Figure 2C), with two notable differences. One
was the detection of a state characterized by short regions
(median size = 400 bp) containing both H3K9me3 and
H3K27me3 (Figure S3A, ‘‘Repr’’ state) that frequently overlap-
ped with lamina-associated domains (LADs) across the entire
genome (15%, 1.3-fold enrichment). The second was a split of
each of the previously designated ‘‘quiescent’’ (Quies and
Quies_G – no marks) and ‘‘transcribed’’ (Tx and Tx_3p –
H3K36me3) states into two states specified by their transition
rather than their emission probabilities (Figure 2A).ot shows all protein coding genes (gray), those with upregulated expression
lot showing the distribution of absolute fold changes in the three comparisons
in this study (CEMT) together with those previously published within the REMC
rank difference in cultured cells compared to freshly isolated cells. (Diff. Expr.,
led here).
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Figure 2. Chromatin State Differences between Cell Types
(A) Chromatin state definitions, histone mark probabilities, overlap with genomic features, and transition probabilities for an 18-state model defined using the
ChromHMM software.
(B) Example of the chromatin state model (ChromHMM) and ChIP-seq signal tracks (y axis = signal per million reads [SPMR]) around the ITGA6 gene (CD49f) for
the LP subset.
(C) Distributions of DNA methylation levels across all chromatin states in the four primary samples analyzed. Boxplots show 10%, 25%, 50%, 75%, and 90%
quantiles.
(D) Aggregated hierarchical clustering based on the normalized Jaccard values of each chromatin state. Fractions show the number of states for which each node
is present in the individual dendrograms.
(E) Heatmap showing the Jaccard value of enhancers associated states with the ChromHMMprofiles generated by the Roadmap Epigenomics Consortium. Only
the top five matches for each sample are represented (black indicates high Jaccard). See complete dataset in Figure S3B.
(F) Jaccard values of each chromatin state between cell types (primary samples only). Each dot shows one pairwise comparison (lines indicate medians).
See also Figure S3.
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Comparison of these chromatin states again showed a
consistent difference between all three mammary cell lines
and the four primary cell types (Figure 2D). In fact, a com-
parison of the enhancer states of these cells with those
of 127 cell and tissue types reported by the Roadmap Epi-
genomics Consortium (Roadmap Epigenomics Consortium
et al., 2015) showed our three cell lines were similar to
cultured epithelial cells derived from breast and skin, and
the BC fraction was most similar to previously analyzed
freshly isolated breast myoepithelial cells (Figures 2E and
S3B). The present findings thus underscore the magnitude
of changes imposed by culture adaptation on the chromatin
landscape (Antequera et al., 1990), in addition to effects on
the transcriptome.
Pairwise comparisons between the chromatin states of each
of the four primary mammary cell types revealed substantive
additional differences, involving 25% of the genome in
each case. Moreover, differences distinguishing LPs, LCs,
and BCs from each other proved to be as extensive as those
distinguishing any one of these from the developmentally unre-
lated SCs (i.e., for each chromatin state, the Jaccard indices
of paired comparisons of SCs with each of the mammary
cell types were not significantly different, p R 0.1 Mann-Whit-
ney; Figure 2F). Enhancer states (abbreviated as Enh, Enh-A,
Enh-G, and Enh-AG) appeared to be the most variable
features, as reported previously (Roadmap Epigenomics
Consortium et al., 2015). Many promoter-associated states
(abbreviated as TSS-Flnk-1, TSS-Flnk-2, and TSS-Flnk-D)
were also highly variable between all cell types (Figures S3C
and S3D).
In summary, the chromatin state models of the data reported
here show that the three major epithelial cell types in normal
adult humanmammary tissue possessmany unique features ex-
tending throughout a large part of their genomes. Nevertheless,
their epigenomes are more different from those of three immor-
talized non-tumorigenic human mammary cell lines by compari-
son to the epigenome of developmentally unrelated SCs isolated
from the same human breast tissue samples. The present pri-
mary mammary cell epigenome datasets also confirm a marked
cell-type specificity in the chromatin states of both enhancer
and promoter regions.Figure 3. H3K27me3 Is Highly Variable at Promoters
(A) Heatmaps showing Spearman correlation coefficients of H3K4me3 (top) and H
subsets of primary cells analyzed.
(B) Density plot showing the distribution of promoters marked by H3K4me3 (top)
(warmer colors indicate higher densities). SPKM, signal per kilobase per million m
(C) Dot plot showing the difference in median levels of histone marks at promoters
comparison.
(D) Venn diagrams showing the numbers of H3K4me3, H3K27me3, and bivalent
(E) Hive plots showing the proportion of H3K27me3-marked promoters specific
green), or not marked (black) in other cell types. Ribbons are proportional to the
(F) Fraction of cell-specific H3K27me3-marked promoters not marked by H3K4m
specific H3K27me3-marked promoters. Individual bars show the H3K4me1 mar
(G) Average plots of H3K4me1-marked cell-type-specific H3K27me3-marked pro
right, LCs.
(H) Fraction of genes associated with cell-type-specific H3K27me3-marked prom
protein coding. Gray boxplots indicate distributions of equally sized random gen
See also Figure S4 and Table S4.Chromatin Features at Promoters Point to a Hierarchy of
Normal Mammary Epithelial Cell States
The importance of H3K4me3 and H3K27me3 modifications
in developmental specification processes (Voigt et al., 2013)
prompted us to examine these modifications at gene promoters
genome-wide, both individually and in combination (Figure 3).
H3K4me3 levels at promoters were highly consistent across all
primary cell types (Spearman correlation coefficient R 0.9).
These correlated positively with the transcript levels of the asso-
ciated protein-coding genes that were differentially expressed
in different cell types. A similar trend was seen for noncoding
RNAs. In general, H3K27me3 levels at promoters weremore var-
iable in all cell types (average Spearman correlation coefficient =
0.69), and these correlated negatively with the levels of tran-
scripts of the associated differentially expressed genes (Figures
3A–3C and S4A–S4E).
We next used false discovery rate (FDR)-based thresholds
(q < 0.01 and at least 400 bp covered) to categorize gene
promoters based on the presence of H3K4me3, H3K27me3, or
both (bivalent) in all three primary mammary subsets (Figure 3D;
Table S4). LCs showed a higher number of H3K27me3-marked
and bivalent promoters compared to BCs, consistent with an
important role of this polycomb-deposited mark in establishing
LC identity, as suggested previously (Maruyama et al., 2011;
Pal et al., 2013). H3K27me3-marked promoters specific to
each cell type were associated with repressed gene expression
(p < 0.01, Mann-Whitney on the group of genes; Figure S4F).
However, a majority of these promoters lacked H3K4me3 in
the other cell types (Figure 3E). Thus, for these genes, transcrip-
tion appears to be independent of promoter modification by
H3K4me3. Approximately 20%–30% of these promoters were
marked by H3K4me1 (Figures 3F and 3G). They were also en-
riched in noncoding RNAs (Figure 3H), of which miRNAs and
lincRNAs were the most frequent types. This suggests that the
role of H3K4me1 and H3K27me3 in regulating noncoding RNA
production seen in other tissues (Amin et al., 2015) also holds
for subsets of freshly isolated normal humanmammary epithelial
cells.
We identified 2,700 bivalent promoters in each of the three
primarymammary cell types. This included the LCs, even though
these cells are thought to represent a terminally differentiated3K27me3 (bottom) marks at promoters in all pairwise comparisons of the four
and H3K27me3 (bottom) in pairwise comparisons between epithelial cell types
apped reads.
of differentially expressed protein-coding genes. Each dot shows one pairwise
ly marked promoters marked in each epithelial cell type.
to each cell type (dark red), being bivalent (blue), and H3K4me3-marked (dark
number of promoters changing marking between two cell types.
e3 in other cell types but marked by H3K4me1. Groups of bars represent cell-
king in each cell type.
moters, notmarked by H3K4me3 in other cell types. Left, BCs; middle, LPs; and
oters, but not marked by H3K4me3 in other cell types, that are classified as
e sets.
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human mammary cell type (Figure 3D). Although heterogeneity
of promoter marking between individual LCs cannot be excluded
as an explanation for the bivalency observed, a similar variability
across donors in gene expression of affected genes was evident
between cell types in three independent studies (Figure S5).
In addition, we found that bivalent promoters in BCs overlap
significantly with the bivalent chromatin states identified in the
Roadmap Epigenomics Consortium dataset for a myoepithelial
cell population (essentially the same as BCs) obtained from a
single donor (Fisher’s p value < 105). Thus it seems unlikely
that the bivalent promoters identified here reflect a mixture of
different promoter marking in the same phenotypes of cells
isolated from different donors.
Most promoters that were bivalent in a given subset of mam-
mary epithelial cells contained at least one of the two marks
in the other two subsets. These changes in promoter marking
correlated with expected changes in gene expression; i.e.,
increased transcript levels were associatedwith loss of promoter
H3K27me3 marks and decreased transcript levels were associ-
ated with loss of promoter H3K4me3 marks (Figures 4A–4C).
More than 90% of the bivalent promoters specific to BCs (422/
459) ‘‘resolved’’ to a display of the same single modification in
both LPs and LCs, with 60% showing H3K4me3 and 40%
showing H3K27me3 modifications. These findings are reminis-
cent of the changes in bivalent promoter modifications that
accompany the differentiation of embryonic stem cells (Bern-
stein et al., 2006).
Gene promoters that were bivalently marked in BCs, but
marked by H3K27me3 in LPs or LCs, included many genes
that encode proteins and TFs with a reported role in regulating
stem cell properties (e.g., SOX17, HOXD10, TCF15, TAL1,
PIWIL1, and the imprinted gene, IGF2). Conversely, gene pro-
moters marked by H3K4me3 in both LCs and LPs with were
significantly enriched in genes encoding proteins implicated
in their differentiation (e.g., ESR1, SOX9, ERBB4, NOTCH2,
RUNX1, CCND1, and EPCAM; p < 0.01, hypergeometric distri-
bution with Bonferroni correction; Figure 4D). These findings
support a model in which genes crucial for luminal differentiation
may be poised in BCs but appear activated in cells that initiate
luminal differentiation.
60% (269/449) of LP-specific bivalent promoters weremarked
by H3K4me3 in BCs and LCs. Associated genes were signifi-
cantly enriched in genes involved in epithelial tissue morphogen-
esis and development (e.g., BMP4, TGFB1, PDGFA, and RXRA;
p < 0.01, hypergeometric distributionwith Bonferroni correction).
This result is again consistent with LPs occupying a stateFigure 4. Bivalent Promoter Differences between Human Mammary Ep
(A) Genome browser tracks of the ChIP-seq signals for H3K4me3 (dark green) and
cell types around the NOTCH3 gene (bivalent in BCs), theMME gene (bivalent in
promoters.
(B) Hive plots showing the proportion of bivalent promoters specific to each cell ty
or not marked (black) in other cell types. Ribbons are proportional to the numbe
(C) Levels of expression of genes associated with cell-specific bivalent promoter
below the x axis label. Black lines indicate medians of each group. p values are
(D) Top five gene ontologies enriched in association with cell-specific bivalent pr
shown in the top right corner.
See also Figure S5.intermediate between BCs and LCs. Interestingly, in LPs,
only 2% (11/449) of the bivalent promoters were marked
by H3K27me3 in BCs and H3K4me3 in LCs, whereas 15%
(68/449) showed the opposite pattern. The latter were also
significantly enriched in genes encoding proteins that regulate
extracellular matrix organization (p < 0.01, hypergeometric distri-
bution with Bonferroni correction). Surprisingly, in both BCs and
LPs, 88% (538/610) of the bivalent promoters specific to LCs
were classified as H3K4me3, and these were enriched in genes
encoding proteins responsible for cell migration, proliferation,
and receptor tyrosine kinases (e.g., VIM, SNAI2, CDK6, KIT,
and EGFR; p < 0.01, hypergeometric distribution with Bonferroni
correction). This latter association suggests an unanticipated
role of this promoter state in repressing processes specific to
BCs and LPs.
Previous studies in breast and other tissues have indicated an
association of bivalently marked promoters with restricted
expression of genes important for lineage determination (Bern-
stein et al., 2006;Maruyama et al., 2011; Visvader and Lindeman,
2012; Voigt et al., 2013). The present results suggest that pro-
moter bivalency plays a broader role in regulating gene expres-
sion among normal human mammary cells. Our analysis also
supports a hierarchical organization of mammary epithelial cell
states in which a bivalent promoter landscape established in
BCs is resolved in LPs and is then maintained in LCs. This in-
cludes some de novo gains of bivalency in LCs suggesting that
this chromatin state may play a role in the repression of genes
involved in proliferation.
Chromatin Features at Enhancers Point to aHierarchy of
Normal Mammary Epithelial Cell States
We next examined the distribution of enhancers in each subset
of primary cells based on the identification of sites marked by
H3K4me1, H3K4me3, H3K27ac and H3K27me3 (Figure 5; Table
S5; see Experimental Procedures for details of this analysis).
Distal ‘‘primed’’ enhancers were defined as any region of chro-
matin marked by H3K4me1, but not also high in H3K4me3,
assuming the latter to have promoter rather than enhancer activ-
ity (Figures 5B, 5C, and S6). We termed those also strongly
marked by H3K27ac as ‘‘active,’’ those strongly co-marked by
H3K27me3 as ‘‘poised,’’ and the very rare regions strongly
marked by both H3K27me3 and H3K27ac (<0.1%) as ‘‘mixed’’
(anticipating this latter group to represent regions of differential
marking in individual cells within the same subset).
Using these definitions, we identified 141,400 putative primed
enhancers (Figures 5D and 5E) with a median distance to theirithelial Cell Types
H3K27me3 (dark red) (y axis = signal per million reads [SPMR) in the epithelial
]LPs) and the EGFR gene (bivalent in LCs). Light gray rectangles indicate gene
pe (blue), being H3K27me3-marked (dark red), H3K4me3-marked (dark green),
r of differently marked promoters in two cell types.
s that show different marks in other cell types. Promoter categories are shown
from a two-tailed Mann-Whitney U test.
omoters that show different marks in other cell types. Promoter categories are
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Figure 5. Identification of Different Classes of Enhancers in Different Human Mammary Cell Subsets
(A) Table showing the different categories of enhancers identified, the histone marking used to define each category (X for absent, O for present, X/O for optional),
and the numbers of enhancers in each cell type.
(B) Expression of THY1 in the four mammary cell types analyzed.
(C) Example of the enhancers identified (Enh track), ChIP-seq signal tracks (y axis = signal per million reads), unmethylated regions (UMR track), and DNA
methylation levels (Fr. Meth.) and coverage (log2 scale) in all cell types around the THY1 gene. Light gray rectangles indicate all enhancers identified.
(D) Heatmap showing the signal for H3K4me1, H3K27ac, and H3K27me3 on each enhancer region identified in LPs, ordered by region size and categorized as off
(gray), primed (green), active (red), poised (blue), and mixed (magenta). Each row represents one enhancer region.
(E) H3K4me1 levels (SPKM) at primed enhancers in all cell types. Each column represents one individual enhancer. Enhancers are grouped based on their
presence in each cell type.
(F) H3K27ac levels (SPKM) at active enhancers in all cell types. Each column represents one individual enhancer. Enhancers are grouped based on their presence
in each cell type.
See also Figure S6 and Table S5.
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closest transcription start site (TSS) of 22 kb. Notably, these en-
hancers overlap significantly (Fisher’s p value < 105 for both
robust and permissive datasets) with enhancers previously in-
ferred from RNA expression data (Andersson et al., 2014). Of
these, 374 overlap with functionally in vivo validated enhancers
(Fisher’s p value < 105) present in the VISTA enhancer browser
(Visel et al., 2007). They were characterized by an overall low
average level of methylation (on average, 50% at enhancer
midpoints, and 75% on equal numbers of randomly selected
genomic regions; Figure S7A). They also showed significant
overlap (Fisher’s p value < 105) with unmethylated regions
(UMRs) and low-methylated regions (LMRs) (Figure S7B), as
defined by applying a hidden Markov model to the WGBS data-
set (Stadler et al., 2011).
The repertoire of active enhancers comprised 40% of those
defined as primed (Figure 5D), of which 30% to 50% were pre-
sent in only one mammary subset (using our thresholds, Figures
5F and 6A). These were associated with 40% to 60% of the
genes showing upregulated expression but only 10% to 30%
of the genes showing downregulated expression in pairwise
comparisons of all cell types (Figures 5B, 5C, 6B, and S6).
A similar, but generally less significant, association was seen
with primed enhancers (excluding those defined as active,
poised or mixed; Figure 6C). Interestingly, regions correspond-
ing to those identified as super enhancers in the mouse mam-
mary gland (Shin et al., 2016) significantly overlapped with sites
identified as active enhancers in human mammary epithelial
cells, but not in the human SCs (Figure S7C). Thus, at least
some of the enhancers identified here as active in human mam-
mary cells appear to also be active in the mouse mammary
gland.
This analysis also revealed cell-type-specific enhancer acti-
vation of many genes with an established role in mammary
epithelial biology. For example, many enhancers in the vicinity
of BC-specific genes were defined as active only in BCs (e.g.,
TP63, THY1, VIM, and SNAI2). Similarly, multiple enhancers
near LC-specific genes were active only in these cells (e.g.,
ESR1, KLF4, FOXA1, S100P, and TBX3), and several enhancers
near KIT and ELF5 were active exclusively in LPs. Likewise, we
found shared active enhancers for many genes that are ex-
pressed at higher levels in BCs and LPs, the two mammary sub-
sets that showhigh progenitor activity (e.g.,KRT5, EGFR, ITGA6,Figure 6. Differential Enhancer Activation in Different Human Mammar
(A) Venn diagrams showing the numbers of enhancers identified in each epithelia
(B and C) Fraction of differentially expressed genes associated with at least one ac
comparison. p values are from a two-tailed Fisher’s test.
(D) Fraction of active enhancers present in only one epithelial cell type marked by
of a comparison between cell types.
(E) Hive plots showing the proportion of active enhancers specific to each cell type
the other cell types. Ribbons are proportional to the number of enhancers chan
Middle: active enhancers specific to LPs. Right: active enhancers specific to LC
(F) Top eight gene ontologies enriched in association with enhancers classified a
(G) Expression of genes associatedwith the gene ontologies shown in (F) andwith
represent medians).
(H) Number of genes whose expression was associated only with active enhancer
or not in other cell types.
(I) Heatmap showing the levels of DNA methylation of the most variable CpG sites
according to their changes in methylation across the epithelial cell types.
See also Figure S7.
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defined as ‘‘poised’’ (on average, only 5% of the primed en-
hancers in each cell type), and these showed a weak inverse
relationship with gene expression (less with upregulated genes
and more with downregulated genes, Figure S7D).
We then compared the state of enhancer priming and activa-
tion within the different mammary subsets. This analysis showed
that up to 40% of the enhancers that were specifically active in
a particular subset were in a primed state in the other two sub-
sets (Fisher p value < 105). This change in enhancer state was
seen more often in LPs than in either LCs or BCs (Figure 6D).
A deeper analysis of H3K4me1 marking of active enhancers
revealed a significant imbalance in cell-specific marking (Fig-
ure 6E). Thus, of the enhancers classified as active only in LCs,
50% (2,500) of those that were primed in LPs were unmarked
in BCs. However, only 30% (1,000) of those primed in BCs
were unmarked in LPs. An analogous pattern was seen for
enhancers classified as active only in BCs, with 60% (4,000)
of those identified as primed in LPs being unmarked in LCs
and only 30% (1,200) of those identified as primed in LCs being
unmarked in LPs. Similar numbers of active LP-specific en-
hancers were also found to be primed in BCs and LCs. However,
approximately half of these were unmarked in the other cell type
(55% and 50% in BCs and LCs, respectively).
This evolving pattern of enhancer activation states is again
consistent with an underlying hierarchy of human mammary
cell differentiation states in which LPs represent an epigenomic
intermediate between BCs and LCs, with enhancer activation
and decommissioning being governed by H3K27ac addition
and removal, respectively. Importantly, functional annotation of
genes associated with enhancers found to be active in BCs
and primed in LPs showed enrichment for terms related to cell
motility and adhesion (p < 0.01 FDR, binomial testing; Figure 6F).
Genes associated with these terms and active enhancers in
BCs were also expressed at a higher level in BCs than in
LPs and LCs (Figure 6G).
Strikingly, >60% of the enhancers uniquely active in one of the
mammary cell types were not marked by H3K4me1 in either of
the other two. This suggests that a majority of enhancers are
activated de novo in each cell type. However,50%of the genes
associated with de novo activated enhancers were also found to
be associated with active enhancers that are primed or active iny Cell Types
l cell type as primed, poised, active, and mixed.
tive (B) or primed (C) enhancer in only one of the two cell types in each pairwise
H3K4me1 in the other two samples. p values are from a two-tailed Fisher’s test
(red), found to be off (gray), primed (green), poised (blue), or mixed (magenta) in
ging marking between two cell types. Left: active enhancers specific to BCs.
s.
s active in BCs, primed in LPs, and off in LCs.
enhancers classified as active in BCs, primed in LPs, and off in LCs. (Black lines
s not primed in other cell types or with active enhancers that were either primed
within UMRs and LMRs. Each row represents one CpG site. Sites are grouped
(legend on next page)
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one of the other two mammary cell types (Figure 6H). This asso-
ciation might be explained by two coexisting modes of enhancer
activation within thesemammary epithelial subsets: one in which
active enhancers fall close to enhancers primed or active in the
other cell subpopulations and one independent of pre-existing
enhancer states.
In summary, from a complete description of human mammary
epithelial cell enhancer activation states, we show that their
enhancer profiles display extensive cell-type specificity, with
no greater similarity between LPs and LCs than between LPs
and BCs, or between LCs and BCs. This epigenomic distinction
of LPs and LCs suggests that enhancer activation plays an
important role in regulating their distinct transcriptional profiles,
with many BC- and LC-specific genes primed for activation or
re-activation in LPs, even though theymaintain a BC- or LC-spe-
cific transcriptional profile. The DNA methylation data obtained
on the same three cell samples also showedmost of the changes
in DNA methylation followed a progressive shift from hyper- to
hypo-methylation, or vice versa from hypo- to hyper-methyl-
ation, in BCs, then LPs, and then LCs. Many CpG sites were
also specifically hypo-methylated in LPs, indicative of a marked
cell-type-specific methylation profile (Figure 6I).
Identification of Distinct TF Regulatory Networks
Wenextmapped theDNAbinding sites of 319 TFs to genomic re-
gions identified as cell-type-specific active enhancers (Figures
7A and 7B). After filtering for significance (p < 106) and expres-
sion (reads per kilobase of transcript per million mapped reads
[RPKM] > 1), binding sites for 64 TFs were found to be enriched
in BCs, 21 in LPs, and 25 in LCs (an average of 72% of the
H3K27ac peaks analyzed contained at least one binding site for
the TFs enriched in the corresponding cell type). This analysis re-
vealed TP63 and FOXA1 to have themost prevalent binding sites
in BCs and LCs, respectively, consistent with their reported se-
lective functions in these cells (Bernardo et al., 2010; Chakrabarti
et al., 2014). Analogously identified TFs in LPs were EHF and
ELF5, two members of the ETS family of TFs with very similar
DNA binding motifs. ELF5 is a recently identified luminal-specific
TF, but a role of EHF in the mammary gland has not been
previously reported.However, EHFhas a known role in the estab-
lishment and maintenance of epithelial cell phenotypes in other
tissues (Albino et al., 2012;Stephens et al., 2013). Anexamination
of several other reported mammary datasets confirmed higher
levels of ELF5 and EHF transcripts in LPs as compared to LCs
and their very low levels in BCs. Comparison of the relative prev-
alence of each of these four enhancer-based TF binding sites
confirmed their respective cell-type specificities.
This analysis also identified a number of other TF binding sites
uniquely prevalent in one of the three normal human mammaryFigure 7. Distinct Transcriptional Regulatory Networks Derived for Ea
(A) Table showing the top five TF binding sites enriched in the sequences associ
(B) Heatmap showing the normalized enrichment value (ln(p value)/max((ln(p
expressed (RPKM > 1) in each epithelial cell type.
(C–E) TF regulatory networks constructed for BCs (C), LPs (D), and LCs (E). Node
proportional to the gene expression correlation of the two nodes connected. Gree
indicate a negative correlation.
See also Tables S6 and S7.
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only intra-genic enhancers were considered (Figure 7B; Table
S6). In BCs, these included binding sites for EGR1 and EGR2,
as well as members of the TEAD EBF and TCF families, and
TP53. In LCs, this analysis identified binding sites for many
members of the AP-1 TF complex, together with ESR1 and
FOXP1. The TFs similarly identified in LPs included GRHL2,
ELF1, and ETS1.
Lastly, we used these enriched TF binding sites to derive a TF
regulatory network for each of the three human mammary cell
types. To construct these networks, we inferred a positive inter-
action between two TFs whenever a binding site for one of the
TFs was found in an active enhancer within 40 kb (62% of all
regions analyzed) of the gene for the other TF and expression
of the two TF genes was positively or negatively correlated (ab-
solute Spearman correlation coefficient > 0.25 from a published
array dataset; Kannan et al., 2013). The networks thus generated
show a high degree of independence in cell-type-specific TFs,
with very few shared nodes and edges (Figures 7C–7E; Table
S7). The network operative in BCs shows a highly interconnected
central group of TFs in which TP63, NF1 (NFIB), EGR2, and ETS1
are the most prominent. In contrast, the network generated for
LCs is much smaller, centered on FOXA1, BATF, and STAT5,
with many TFs potentially contributing to the regulation of
ESR1. The network derived for LPs is dominated by ELF5 and
EHF, which regulate each other, as well as EHF regulating itself.
Interestingly, the LP network contains a module common to the
BC network that involves NFIB and ETS1, and it includes five
TFs present in the LC network (ATF3, BATF, FOS, FOSL1, and
FOSL2), reinforcing the concept of LPs as an epigenomically in-
termediate state between BCs and LCs.
These findings illustrate the power of complete epigenome
profiles to reveal novel information about mechanisms that con-
trol the transcriptional landscape of biologically complex normal
adult human tissues. We anticipate the networks defined here
will be further refined by a deeper subsetting of the populations
analyzed, as has been suggested (Visvader and Stingl 2014).
However, the fact that the present datasets have been generated
from very large pools of highly purified cells isolated from six
donors makes it likely that they will be generally representative
of normal breast cells from premenopausal women.
EXPERIMENTAL PROCEDURES
Breast Tissue Dissociation, Cell Sorting, and In Vitro Progenitor
Assays
Histologically normal breast tissue was obtained with informed consent
from six healthy premenopausal adult female donors undergoing reduction
mammoplasty surgeries and used according to procedures approved by the
Research Ethics Board of the University of British Columbia. Fresh tissuech Mammary Epithelial Subpopulation
ated with active enhancers specific to each epithelial cell type.
value))) of all TF binding sites found to be significantly enriched (p < 106) and
size is proportional to the enrichment value shown in (B), and edge thickness is
n arrows between the two genes indicate a positive correlation. Magenta lines
was viably cryopreserved as enzymatically isolated organoids and then
thawed and dissociated into single-cell suspensions and the four defined
mammary cell types isolated by fluorescence-activated cell sorting (FACS)
(Figure 1A) as previously described (Kannan et al., 2014). Similar sub-
sets from each sort were combined in the same proportions to obtain pools
ofR50 3 106 cells for each subset. The cells were washed in PBS containing
protease inhibitors and frozen until processed for ChIP-seq or DNA/RNA
extraction. The progenitor content of each subset was determined indepen-
dently, as previously described (Kannan et al., 2013).
Production of Reference Epigenomes
RNA and DNA extraction and ChIP library construction and sequencing were
performed following the guidelines formulated by the IHEC (http://www.
ihec-epigenomes.org). These guidelines, as well as the standard operating
procedures for RNA-seq, ChIP-seq, and whole-genome bisulfite se-
quencing library construction, are available at http://www.epigenomes.ca/
protocols-and-standards or by request.
Epigenomic Data Analysis
Detailed methods explaining the data analysis performed for the RNA-seq,
ChIP-seq, and WGBS datasets are provided in Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The accession numbers for the raw sequence datasets reported in this
paper are EGA: EGAS00001000552 and EpIRR: IHECRE00000223,
IHECRE00000228, IHECRE00000231, IHECRE00000242, IHECRE00000001,
IHECRE00000225, and IHECRE00000227. Processed signal tracks are also
available at http://www.epigenomes.ca.
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